T1D Risk Score: microRNA Biomarker
- A new risk score for type 1 diabetes (T1D) has been developed using microRNAs (miRNAs) found in plasma samples.This new PREDICT T1D signature could improve early detection and...
- the study involved analyzing plasma samples from various groups, including individuals recently diagnosed with T1D, healthy controls, and siblings of those with T1D.Samples where collected from multiple locations,...
- Researchers assessed the performance of the risk score using a separate validation dataset from australia, Canada, India, New Zealand, and the United States.
Uncover a groundbreaking progress in T1D risk assessment. Researchers have engineered a novel risk score for type 1 diabetes (T1D) leveraging microRNAs (miRNAs), perhaps revolutionizing early detection and proactive intervention. this innovative T1D risk score, developed from plasma samples, offers a promising step forward in identifying individuals at risk of developing the condition. The study, spanning diverse geographical locations like Australia, Denmark, and India, underscores the global relevance of this advancement. The score’s performance was rigorously assessed, highlighting its potential to stratify drug efficacy.News directory 3 brings you the latest on this critical research. Discover what’s next for early T1D detection and prevention.
New Type 1 Diabetes Risk Score Developed using miRNAs
Updated June 05,2025
A new risk score for type 1 diabetes (T1D) has been developed using microRNAs (miRNAs) found in plasma samples.This new PREDICT T1D signature could improve early detection and intervention for individuals at risk of developing the condition.
the study involved analyzing plasma samples from various groups, including individuals recently diagnosed with T1D, healthy controls, and siblings of those with T1D.Samples where collected from multiple locations, including Australia, Denmark, Hong Kong, and India. Diagnostic criteria for T1D varied across these regions but adhered to established standards.
Researchers assessed the performance of the risk score using a separate validation dataset from australia, Canada, India, New Zealand, and the United States. The study also examined the ability of PREDICT T1D miRNAs to stratify drug efficacy in an imatinib intervention study.
Ethical approvals were obtained from the respective institutional human ethics committees at each site. Tissue and plasma samples were collected using standardized procedures and stored frozen until use. RNA isolation was performed using an automated platform, and samples with hemolysis were excluded.
The relative abundance of miRNAs was calculated, and substantially different miRNAs were identified using statistical tests. A random forest machine learning workflow was used to test and validate a set of 50 meaningful miRNAs in a multicontext set of samples.
The miRNA abundance of the 50 PREDICT T1D miRNAs was compared between participants with T1D and controls, or participants with T1D and siblings, using statistical tests. classification models were built on training datasets using the random forest workflow.
What’s next
Further research is needed to validate and refine the risk score, and also to explore its potential clinical applications in early detection and prevention of type 1